Search Results for "Colchicine And Rivaroxaban"

21:06 EDT 26th October 2016 | BioPortfolio

Matching Channels


Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Optimal dosing of rivaroxaban is undefined

The faulty INRatio device used in the rivaroxaban ROCKET atrial fibrillation trial1 is particularly important in light of another drawback to this novel oral anticoagulant (NOAC). Rivaroxaban has the....

Does Colchicine Prevent Adverse Cardiovascular Events in Gout Patients?

This retrospective study suggests that anti-inflammatory therapies, such as colchicine, are associated with lower CV risk.

Rivaroxaban in the Real World

A large Phase IV registry study shows that rivaroxaban is associated with a very low incidence of major bleeding, death, or stroke. Also, adherence to therapy was much higher than observed in other st...

Treatment with colchicine is not linked to reducing cardiovascular mortality

An evidence review of 39 clinical trials found that patients who received continuous long-term treatment with colchicine had no reduction in all-cause mortality or cardiovascular mortality.

BRIEF-Hikma says U.S. Court of Appeals upholds regulatory approval of colchicine

* Fda's regulatory approval of hikma's colchicine 0.6 mg capsule product was upheld.

Fewer Major Bleeds on Dabigatran vs Rivaroxaban for AF

In elderly patients with nonvalvular atrial fibrillation (AF), dabigatran and rivaroxaban provide comparable protection against thromboembolic stroke but dabigatran is safer, according to a new analys...

Rivaroxaban: new tool for antiphospholipid syndrome (lupus condition)

Rivaroxaban could be a safe treatment option for antiphospholipid syndrome, an important finding for people with lupus, says research published in The Lancet Haematology. Thrombotic antiphospholipid s...

Colchicine and Prevention of Cardiovascular Events

This Clinical Evidence Synopsis summarizes a Cochrane review of clinical trials comparing the effects of long-term colchicine treatment with usual care or placebo on cardiovascular events in patients ...

Matching PubMed Articles

Colchicine for prevention and treatment of cardiac diseases: a meta-analysis.

Colchicine has been suggested to be beneficial in preventing recurrent pericarditis. The goal of this study was to review all randomized controlled trials that assess the use of colchicine for the pre...

Colchicine for prevention of cardiovascular events.

Colchicine is an anti-inflammatory drug that is used for a wide range of inflammatory diseases. Cardiovascular disease also has an inflammatory component but the effects of colchicine on cardiovascula...

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

The aims of this study were to investigate the effects of rivaroxaban on routine coagulation assays using our local, widely available, reagents and to study the relationship between sensitive coagulat...

Colchicine and Prevention of Cardiovascular Events.

Is continuous long-term treatment with colchicine associated with lower rates of all-cause mortality and myocardial infarction and higher rates of adverse events?

Activated protein C resistance in patients following venous thromboembolism receiving rivaroxaban versus vitamin K antagonists: assessment using Russell viper venom time-based assay.

Activated protein C resistance (APC-R) is assessed as part of thrombophilia screening, preferably in patients not taking oral anticoagulants. Rivaroxaban is known to alter some APC-R assays. To our kn...

Search Whole site using Google

Quick Search
Advertisement Advertisement